Find clinical trials for Pancreatic Cancer in Montréal, QC
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Pancreatic Cancer trials near Montréal, QC, CAN:
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer...
Montréal, Quebec, Canada and 1 other location
Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either FOLFIRINOX o ...
Phase 2
Montreal, Quebec, Canada
to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor...
Phase 1
Montreal, Quebec, Canada and 21 other locations
and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...
Phase 2
Montréal, Quebec, Canada and 65 other locations
This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age....
Phase 1, Phase 2
Montreal, Quebec, Canada and 76 other locations
of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid ...
Phase 2
Montreal, Quebec, Canada and 48 other locations
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially d...
Phase 1, Phase 2
Montréal, Quebec, Canada and 13 other locations
This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8...
Phase 1
Montréal, Quebec, Canada and 7 other locations
(E7080/MK-7902) in participants with triple negative breast cancer (TNBC), ovarian cancer, gastric cancer, colorectal cancer...
Phase 2
Montreal, Quebec, Canada and 87 other locations
deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors.This study will consist of Part 1 which includes 7 cohorts of: uroth ...
Phase 2
Montreal, Canada and 120 other locations
Clinical trials
Research sites
Resources
Legal